1,2-Dichloroethane → HCID 86671987, compound
Reaction equation
[C:1]([N:4]1[CH2:7][C:6]2([CH2:16][C:15](=[O:17])[C:14]3[C:9](=[CH:10][CH:11]=[C:12](/[CH:18]=[CH:19]/[C:20](O)=[O:21])[CH:13]=3)[O:8]2)[CH2:5]1)(=[O:3])[CH3:2].C(Cl)CCl.C1C=CC2N(O)N=NC=2C=1.[NH2:37][O:38][CH:39]1[CH2:44][CH2:43][CH2:42][CH2:41][O:40]1>C(Cl)Cl>[C:1]([N:4]1[CH2:7][C:6]2([CH2:16][C:15](=[O:17])[C:14]3[C:9](=[CH:10][CH:11]=[C:12](/[CH:18]=[CH:19]/[C:20]([NH:37][O:38][CH:39]4[CH2:44][CH2:43][CH2:42][CH2:41][O:40]4)=[O:21])[CH:13]=3)[O:8]2)[CH2:5]1)(=[O:3])[CH3:2]Participants
6
Procedure
A suspension of (E)-3-[1′-acetyl-4-oxo-spiro(chromane-2,3′-azetidine)-6-yl]-acrylic acid (100 mg, 0.30 mmol) in DCM (3 ml) was treated with TEA (0.060 ml, 0.49 mmol) and then with EDC (94 mg, 0.49 mmol), HOBt (67 mg, 0.49 mmol) and NH2OTHP (50 mg, 0.43 mmol) following the procedure described in Example 30, Step B, giving (E)-3-[1′-acetyl-4-oxo-spiro(chromane-2,3′-azetidine)-6-yl]-N-(tetrahydro-pyran-2-yloxy)-acrylamide (36 mg) as a white solid.
Sources & evidence
- ORD record
- ord-ff7f85deba7d49bfa15a964775882a07
- Source dataset
- uspto-grants-2015_03
- Patent number
- US08980877B2
Reaction notes
Loading…